GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (NAS:CDXC) » Definitions » Piotroski F-Score
中文

ChromaDex (ChromaDex) Piotroski F-Score

: 6 (As of Today)
View and export this data going back to 2008. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ChromaDex has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for ChromaDex's Piotroski F-Score or its related term are showing as below:

CDXC' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 6
Current: 6

During the past 13 years, the highest Piotroski F-Score of ChromaDex was 6. The lowest was 3. And the median was 4.


ChromaDex Piotroski F-Score Historical Data

The historical data trend for ChromaDex's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChromaDex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 4.00 3.00 6.00

ChromaDex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 6.00 6.00 6.00

Competitive Comparison

For the Biotechnology subindustry, ChromaDex's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChromaDex Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, ChromaDex's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where ChromaDex's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -1.902 + -2.191 + -0.959 + 0.114 = $-4.94 Mil.
Cash Flow from Operations was 2.792 + 3.28 + 0.396 + 0.649 = $7.12 Mil.
Revenue was 22.556 + 20.323 + 19.495 + 21.196 = $83.57 Mil.
Gross Profit was 13.518 + 12.356 + 11.969 + 12.937 = $50.78 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(54.057 + 53.768 + 53.171 + 53.483 + 54.964) / 5 = $53.8886 Mil.
Total Assets at the begining of this year (Dec22) was $54.06 Mil.
Long-Term Debt & Capital Lease Obligation was $2.58 Mil.
Total Current Assets was $49.53 Mil.
Total Current Liabilities was $20.62 Mil.
Net Income was -7.74 + -6.397 + -0.985 + -1.418 = $-16.54 Mil.

Revenue was 17.259 + 16.732 + 17.063 + 20.996 = $72.05 Mil.
Gross Profit was 10.532 + 10.042 + 10.207 + 12.016 = $42.80 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(57.84 + 52.93 + 46.613 + 45.665 + 54.057) / 5 = $51.421 Mil.
Total Assets at the begining of last year (Dec21) was $57.84 Mil.
Long-Term Debt & Capital Lease Obligation was $3.56 Mil.
Total Current Assets was $46.57 Mil.
Total Current Liabilities was $17.87 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ChromaDex's current Net Income (TTM) was -4.94. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

ChromaDex's current Cash Flow from Operations (TTM) was 7.12. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-4.938/54.057
=-0.09134802

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-16.54/57.84
=-0.28596127

ChromaDex's return on assets of this year was -0.09134802. ChromaDex's return on assets of last year was -0.28596127. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

ChromaDex's current Net Income (TTM) was -4.94. ChromaDex's current Cash Flow from Operations (TTM) was 7.12. ==> 7.12 > -4.94 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=2.575/53.8886
=0.04778376

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=3.561/51.421
=0.06925186

ChromaDex's gearing of this year was 0.04778376. ChromaDex's gearing of last year was 0.06925186. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=49.534/20.622
=2.40199787

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=46.567/17.869
=2.6060216

ChromaDex's current ratio of this year was 2.40199787. ChromaDex's current ratio of last year was 2.6060216. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

ChromaDex's number of shares in issue this year was 75.126. ChromaDex's number of shares in issue last year was 73.923. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=50.78/83.57
=0.60763432

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=42.797/72.05
=0.59399028

ChromaDex's gross margin of this year was 0.60763432. ChromaDex's gross margin of last year was 0.59399028. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=83.57/54.057
=1.54596075

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=72.05/57.84
=1.24567773

ChromaDex's asset turnover of this year was 1.54596075. ChromaDex's asset turnover of last year was 1.24567773. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+1+0+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

ChromaDex has an F-score of 6 indicating the company's financial situation is typical for a stable company.

ChromaDex  (NAS:CDXC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


ChromaDex Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of ChromaDex's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ChromaDex (ChromaDex) Business Description

Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.
Executives
Brianna Gerber officer: SVP Finance / Interim CFO C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd 10 percent owner C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Jaksch Frank L Jr director, 10 percent owner, officer: Chief Executive Officer 10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Robert N Fried director 100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing 10 percent owner 79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly 10 percent owner SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi director C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen director C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Kristin Patrick director 3329 CAY DRIVE, SHERMAN OAKS CA 91423
Ng Wang Yu Gary director ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington officer: General Counsel 53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr officer: Chief Financial Officer MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245

ChromaDex (ChromaDex) Headlines

From GuruFocus

ChromaDex Named Brianna Gerber Chief Financial Officer

By Business Wire Business Wire 01-05-2023